Oncolytic viruses: From bench to bedside with a focus on safety

被引：106

作者：

Buijs, Pascal R. A. ^{[1
]}

Verhagen, Judith H. E. ^{[2
]}

van Eijck, Casper H. J. ^{[1
]}

van den Hoogen, Bernadette G. ^{[3
]}

机构：

[1] Univ Med Ctr, Dept Surg, Erasmus MC, Rotterdam, Netherlands

[2] Univ Med Ctr, Dept Gastroenterol, Erasmus MC, Rotterdam, Netherlands

[3] Univ Med Ctr, Erasmus MC, Dept Virosci, Rotterdam, Netherlands

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2015年 / 11卷 / 07期

关键词：

HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; NEWCASTLE-DISEASE VIRUS; SENECA VALLEY VIRUS; PHASE-I TRIAL; CONDITIONALLY-REPLICATIVE ADENOVIRUS; GENE-THERAPY; MEASLES-VIRUS; NUCLEOTIDE-SEQUENCE; MALIGNANT-MELANOMA;

D O I：

10.1080/21645515.2015.1037058

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus. © 2015, Taylor & Francis Group, LLC.

引用

页码：1573 / 1584

页数：12

共 150 条

[1] Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors [J].

Alba, Raul ;

Bradshaw, Angela C. ;

Coughlan, Lynda ;

Denby, Laura ;

McDonald, Robert A. ;

Waddington, Simon N. ;

Buckley, Suzanne M. K. ;

Greig, Jenny A. ;

Parker, Alan L. ;

Miller, Ashley M. ;

Wang, Hongjie ;

Lieber, Andre ;

van Rooijen, Nico ;

McVey, John H. ;

Nicklin, Stuart A. ;

Baker, Andrew H. .

BLOOD, 2010, 116 (15) :2656-2664

[2] CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].

Alemany, R ;

Curiel, DT .

GENE THERAPY, 2001, 8 (17) :1347-1353

[3] Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma [J].

Altomonte, Jennifer ;

Marozin, Sabrina ;

Schmid, Roland M. ;

Ebert, Oliver .

MOLECULAR THERAPY, 2010, 18 (02) :275-284

[4]

Andtbacka RHI, 2014, 8 INT C ONC VIR THER

[5] VSV-tumor selective replication and protein translation [J].

Barber, GN .

ONCOGENE, 2005, 24 (52) :7710-7719

[6] Development of a Targeted Gene Vector Platform Based on Simian Adenovirus Serotype 24 [J].

Belousova, Natalya ;

Mikheeva, Galina ;

Xiong, Chiyi ;

Soghomonian, Suren ;

Young, Daniel ;

Le Roux, Lucia ;

Naff, Katherine ;

Bidaut, Luc ;

Wei, Wei ;

Li, Chun ;

Gelovani, Juri ;

Krasnykh, Victor .

JOURNAL OF VIROLOGY, 2010, 84 (19) :10087-10101

[7] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[8]

Blanc C, 2014, 8 INT C ONC VIR THER

[9] Measles virus as an oncolytic vector platform [J].

Blechacz, Boris ;

Russell, Stephen J. .

CURRENT GENE THERAPY, 2008, 8 (03) :162-175

[10] Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans [J].

Bramante, Simona ;

Koski, Anniina ;

Kipar, Anja ;

Diaconu, Iulia ;

Liikanen, Ilkka ;

Hemminki, Otto ;

Vassilev, Lotta ;

Parviainen, Suvi ;

Cerullo, Vincenzo ;

Pesonen, Saila K. ;

Oksanen, Minna ;

Heiskanen, Raita ;

Rouvinen-Lagerstroem, Noora ;

Merisalo-Soikkeli, Maiju ;

Hakonen, Tiina ;

Joensuu, Timo ;

Kanerva, Anna ;

Pesonen, Sari ;

Hemminki, Akseli .

INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (03) :720-730

← 1 2 3 4 5 6 7 8 9 10 →